Corporate Banner
Satellite Banner
Biologics & Bioprocessing
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Yale Researcher Says Whooping Cough Vaccines Effective, Despite Outbreaks

Published: Friday, November 30, 2012
Last Updated: Friday, November 30, 2012
Bookmark and Share
Dr. Shapiro’s editorial was published in the Nov. 28 issue of Journal of the American Medical Association.

Despite recent outbreaks of pertussis (whooping cough) - a highly contagious bacterial disease that is preventable by the current pertussis vaccines - Yale researcher Dr. Eugene Shapiro maintains in an editorial that the vaccines are effective and should still be administered.

Shapiro said that although acellular vaccines may be suboptimal, they are still quite effective and should be focused on pregnant women, infants, and caregivers.

“It is most important to try to protect infants, who have the most severe illnesses and highest mortality from pertussis,” said Shapiro, professor of pediatrics.

Shapiro continued, “The highest rates of both hospitalizations and deaths from pertussis occurred in children younger than two months.”

The resurgence of pertussis in the United States, even among those who have been vaccinated in the past, has led many experts to question the long-term duration of immunity.

Published in the Nov. 28 issue of Journal of the American Medical Association (JAMA), Shapiro’s editorial stresses that while there is speculation that the outbreak is linked to the vaccine’s waning immunity over time, there is no definitive evidence that this is the primary or sole reason for increases in reported cases of pertussis.

The original whole-cell pertussis vaccine DTwP, which also included vaccines against diphtheria and tetanus, was introduced for childhood immunization in the 1940s.

But acellular combination pertussis vaccines (DTaP) replaced DTwP in the early 1990s because the whole-cell vaccine had high rates of side-effects such as fever and inflammation at the injection site.

DTaP uses purified components to reduce side-effects, but Shapiro said there is not enough data on the duration of the DTaP vaccine’s immunity.

“There have been periodic outbreaks in the past even with the whole cell vaccine, so there is no way to know for sure that the outbreaks are linked to the accelular vaccine,” he said. “There is no definitive evidence as to why there are increased outbreaks, and there may be multiple reasons for it.”


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,100+ scientific posters on ePosters
  • More than 4,500+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

CNS Inflammation: A Pathway and Possible Drug Target
Scientists have long known that the central nervous system (CNS) has a remarkable ability to limit excessive inflammation in the presence of antigens or injury, but how it works has been unclear.
Tuesday, April 12, 2016
Creating More Potent Vaccines
Yale researchers uncovered a new role for a type of immune cell, known as regulatory T cells, in promoting long-term immunity.
Wednesday, July 08, 2015
Racial and Economic Gap in Awareness of Lifesaving HPV Vaccine
Research finds worrisome racial, economic, educational, and gender gaps in awareness about the lifesaving vaccine for HPV.
Monday, June 10, 2013
Yale Researchers Trick Bacteria to Deliver a Safer Vaccine
Yale researchers have developed a new trick, using bacteria’s own cellular mistakes to deliver a safe vaccine.
Tuesday, March 19, 2013
Pioneering Yale Immunologist Receives Inaugural NIH Award
Renowned Yale immunologist Ruslan Medzhitov has been awarded the inaugural Lurie Prize in the Biomedical Sciences from the Foundation for the National Institutes of Health (FNIH).
Thursday, February 28, 2013
For Drug Makers, New 3-D Control Opens Wealth of Options
Scientists have demonstrated a new, highly versatile approach for quickly assembling drug-like compounds, establishing a broad new route to drug discovery and medical treatment.
Monday, February 18, 2013
Yale Scientists Find a Way to Make Disease-Causing Proteins Vulnerable to Drugs
Researchers have identified a novel way to design drugs for previously inaccessible proteins.
Friday, July 27, 2012
Scientific News
Developing a More Precise Seasonal Flu Vaccine
During the 2014-15 flu season, the poor match between the virus used to make the world’s vaccine stocks and the circulating seasonal virus yielded a vaccine that was less than 20 percent effective.
Fighting Cancer with Borrowed Immunity
A new step in cancer immunotherapy: researchers from the Netherlands Cancer Institute and University of Oslo/Oslo University Hospital show that even if one's own immune cells cannot recognize and fight their tumors, someone else's immune cells might.
Modified Microalgae Converts Sunlight into Valuable Medicine
A special type of microalgae can soon produce valuable chemicals such as cancer treatment drugs and much more just by harnessing energy from the sun.
Immune Cells Remember Their First Meal
Scientists at the University of Bristol have identified the trigger for immune cells' inflammatory response – a discovery that may pave the way for new treatments for many human diseases.
Paper Filter Can Remove Viruses from Water
A new paper filter can purify water from viruses, even the most difficult and contagious.
Large-scale HIV Vaccine Trial to Launch in South Africa
NIH-funded study will test safety, efficacy of vaccine regimen.
New HIV Vaccine Target Discovered
NIH-Led team have discovered a new vaccine target site on HIV.
Mimicking Evolution to Create Novel Proteins
A study by researchers in the Kuhlman lab offers a new route to design the 'cellular machines' needed to understand and battle diseases.
Antibody Therapy Opens Door to Potential New Treatment for HIV
Researchers at Rockefeller University show how a broadly neutralizing antibody could be used to help fight HIV.
Investigational Malaria Vaccine Protects Healthy U.S. Adults
Researchers at NIH have found that the malaria vaccine protected a small number of healthy, malaria-naïve adults in the U.S. from infection for more than one year after immunization.
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,100+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,500+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!